Author

R. A. Tripp

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 2 Biochemistry· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 4 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

J. Crabtree· 3 shared J. Murray· 2 shared R. J. Hogan· 2 shared A. Banerjee· 1 shared A. D. Gingerich· 1 shared A. D. Truax· 1 shared A. F. Lingappa· 1 shared A. Kipar· 1 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

J. Crabtree

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

mRNA Vaccines Encoding Influenza Virus Hemagglutinin (HA) Elicits Immunity in Mice from Influenza A Virus Challenge

Z. B. Reneer, H. C. Bergeron, S. Reynolds, E. Thornhill-Wadolowski, L. Feng, M. Bugno, A. D. Truax, R. A. Tripp

This study shows mRNA vaccines encoding influenza HA proteins protect mice against influenza challenge, eliciting neutralizing antibodies and reducing viral titers.

bioRxiv · Nov 15, 2023Immunology

Structural basis for ultrapotent neutralization of human metapneumovirus

A. Banerjee, J. Huang, S. Rush, J. Murray, A. D. Gingerich, F. Royer, C.-L. Hsieh, R. A. Tripp, J. S. McLellan, J. J. Mousa

This study identifies a potent monoclonal antibody against hMPV and determines its structure, revealing a novel epitope for therapeutic development.

bioRxiv · Mar 14, 2022 · PreprintImmunology

Probenecid Inhibits SARS-CoV-2 Replication In Vivo and In Vitro

J. Murray, R. J. Hogan, D. E. Martin, K. Blahunka, F. Sancillo, R. Balyan, M. Lovern, R. Still, R. A. Tripp

This study shows probenecid inhibits SARS-CoV-2 replication in mammalian cells and a hamster model, with achievable plasma concentrations supporting its potential clinical use.

bioRxiv · May 21, 2021Microbiology

A Pan-respiratory Antiviral Chemotype Targeting a Host Multiprotein Complex

M. Michon, A. Mueller-Schiffmann, A. F. Lingappa, S. F. Yu, L. Du, F. Deiter, S. Mallesh, J. Crabtree, U. F. Lingappa, A. Macieik, L. Mueller, P. N. Ostermann, M. Andree, O. Adams, H. Schaal, , K

The paper identifies a novel antiviral chemotype effective against multiple respiratory viruses by targeting a host multi-protein complex involved in viral lifecycle and innate immunity.

bioRxiv · Jan 17, 2021Biochemistry

Losartan promotes cell survival following SARS-CoV-2 infection in vitro

R. Nejat, A. S. Sadr, B. T. Freitas, J. Crabtree, S. D. Pegan, R. A. Tripp, D. J. Najafi

This study shows that Losartan reduces SARS-CoV-2 replication in Vero E6 cells by 80% pre-infection and 70% post-infection, promoting cell survival with low side-effects.

bioRxiv · Dec 27, 2020 · PreprintPharmacology & Toxicology

Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2

N. Iwanaga, L. Cooper, L. Rong, B. Beddingfield, J. Crabtree, R. A. Tripp, X. Qin, J. Kolls

This paper develops a modified ACE2-IgG1 fusion protein with enhanced in vivo activity against SARS-CoV2, showing improved lung bioavailability and viral neutralization.

bioRxiv · Jun 15, 2020 · PreprintImmunology

The WD and linker domains of ATG16L1 required for non canonical autophagy limit lethal influenza A virus infection at epithelial surfaces.

Y. Wang, W. Zhang, M. Jefferson, P. Sharma, B. Bone, A. Kipar, J. L. Coombes, T. Pearson, A. Mann, A. Zhekova, Y. Bao, R. A. Tripp, Y. Yamauchi, S. R. Carding, U. Mayer, , T. Wileman

This study shows that non-canonical autophagy, mediated by the WD and linker domains of ATG16L1, protects against lethal influenza A virus infection by limiting viral replication and inflammation in airway epithelial cells.

bioRxiv · Jan 15, 2020 · PreprintMicrobiology